CPD-002
CPD-002 is an inhibitor for vascular endothelial growth factor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2617376-08-4
- Fòrmula: C17H16N4O2S
- Peso molecular:340.40
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas VEGFR
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | GI50 |
150 nM
Compound: 6
|
Growth inhibition of mouse BaF3 cells harboring TEL-VEGFR2 incubated for 72 hrs by CCK-8 assay
Growth inhibition of mouse BaF3 cells harboring TEL-VEGFR2 incubated for 72 hrs by CCK-8 assay
|
[PMID: 37216810] |
CPD-002 (0-64 μM, 24-48 h) exhibits cytotoxicity for cells HUVECs and MH7A, in a dose-dependent manner[1].
CPD-002 (0-8 μM, 24 h) inhibits VEGF-induced cell migration and invasion of HUVECs, through suppression of F-actin expression, and chemotactic response to MH7A cell-released chemoattractants[1].
CPD-002 (0-8 μM) exhibits anti-inflammatory activity through inhibition of the inflammatory mediators like TNF-α, IL-1β, IL-6, IL-8, MMP2 and MMP9, and thus inhibits synovial angiogenesis[1].
CPD-002 (0-8 μM, 9 days) inhibits HUVECs tube formation and aortic ring sprout formation in ex vivo rat aortic ring assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HUVECs and MH7A
-
Concentration:0-64 μM
-
Incubation Time:24-48 h
-
Result:Inhibited cell viability in a dose-dependent manner.
-
Cell Line:HUVECs
-
Concentration:0-8 μM
-
Incubation Time:24 h
-
Result:Inhibited HUVECs migration in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:adjuvant-induced arthritis (AIA) Sprague Dawley rats models[1]
-
Dosage:15-60 mg/kg
-
Administration:i.p., once daily for 14 days
-
Result:Ameliorated paw swelling, joint damage, and synovial angiogenesis.
Chemical Information
-
No. CAS 2617376-08-4
-
Peso molecular 340.40
-
Fòrmula C17H16N4O2S
-
SMILES
CNC(C1=CC=CC=C1SC2=CC3=C(C(NC(C)=O)=NN3)C=C2)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CPD-002 Related Classifications
HY-163533 Related Classifications
Powered by Bioz